Korean Biotech Takes Home-Built Strengths to BIO USA 2026

When Korean pharmaceutical and biotech executives worked the four days of BIO USA 2026 — moving between partnering meetings, results presentations and networking floors — the common thread was not a new overseas bet but a pitch rooted in capabilities each company had already built inside Korea. From AI-driven genome interpretation to commercial manufacturing know-how, the executives sold the domestic base as the differentiator.

MediSapiens Bets on AI That Reads Genetic Variants

MediSapiens, led by chief executive Kang Sang-gu, used the conference to position its AI-based genome analysis platform, MedyCVi, as a clinician’s assistant rather than a black box. The tool is designed to help doctors judge whether a patient’s genetic variant is pathogenic — one of the most time-consuming interpretive steps in clinical genomics — and the company framed it as software that works alongside physicians instead of replacing their judgment. That positioning matters in a market where diagnostic AI has to win the trust of the clinicians it aims to support.

Lotte Biologics Sells Manufacturing Reproducibility, Not Just Capacity

For Lotte Biologics, the message from technology development head Han Jae-jun was that quality can be reproduced across sites — the company’s argument for winning contract manufacturing and technology-transfer work. The Seoul-headquartered firm, formed in June 2022 as a Lotte Corporation unit, entered biopharma manufacturing by acquiring a Bristol Myers Squibb plant with 40,000-liter capacity in May 2022, giving it a running commercial operation in Syracuse, New York from day one.

That operating experience is now being carried into its home build-out. Groundwork on the first plant at the Songdo campus in Incheon began in July 2023, with construction targeted for completion in 2025 and startup in 2027. The full plan calls for three plants at 120,000 liters each, underpinned by roughly 4.6 trillion won of investment through 2030. Against that industrial scale, the company still ran lean, with a workforce of 128 as of 2023 — a reminder that its pitch leans on transferable process knowledge as much as on floor space.

G2G Bio Arrives With a Fresh Listing and an Open Question

G2G Bio, founded by Lee Hee-yong in March 2017 and named for the phrase “Good to the Globe Biotech Company,” came to the conference as a newly public company, having listed on KOSDAQ on August 14, 2025. It reached the market after earning an A grade in a 2024 technology evaluation, with Mirae Asset Securities as underwriter.

The financials behind that debut show an early-stage developer still spending ahead of revenue: 2023 sales of about 700 million won against operating and net losses of roughly 10.5 billion won each, with 52 employees. One cloud over its pipeline is intellectual property — in 2025 the Korean Intellectual Property Office upheld a challenge by Peptron and invalidated a G2G Bio patent tied to obesity treatment, an outcome that sharpens the stakes for how the company defends its platform going forward.

The Common Denominator

Across these companies the export product is increasingly Korean-built capability itself — an AI interpretation engine, a transferable manufacturing method, a platform freshly validated by public markets. BIO USA is where that domestic groundwork gets tested against global demand, and for this cohort the four days were less about chasing a foreign anchor than about proving what was already assembled at home can travel.